Market revenue in 2023 | USD 72.1 million |
Market revenue in 2030 | USD 191.5 million |
Growth rate | 15% (CAGR from 2023 to 2030) |
Largest segment | (crispr)/cas9 |
Fastest growing segment | (CRISPR)/Cas9 |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease |
Key market players worldwide | Merck KGaA, Cibus Inc Ordinary Shares - Class A, Recombinetics, Sangamo Therapeutics Inc, Editas Medicine Inc, Precision BioSciences Inc, CRISPR Therapeutics AG, Intellia Therapeutics Inc, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, AstraZeneca PLC, Takara Bio Inc, Horizon Discovery, Danaher Corp, Genscript Biotech Corp Class H, New England Biolabs, Origene Technologies, Bluebird bio Inc, Lonza Group Ltd, Thermo Fisher Scientific Inc |
(crispr)/cas9 was the largest segment with a revenue share of 47.43% in 2023. Horizon Databook has segmented the Denmark genome editing market based on (crispr)/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2018 to 2030.
Denmark's Danish National Genome Center offers genetic testing to over 60,000 patients for personalized treatment. The Danish initiative aims to deliver personalized medicine and genetic analysis to patients directly and provide precise diagnosis & treatment.
Young people and children with rare diseases are the first beneficiaries of this initiative. In April 2022, the Danish National Genome Center partnered with Lifebit, aiming to deliver personalized medicine in the country.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account